Biotech Stocks Newsletter – March 21, 2018

0
624

These Leaders In Biotech May Know Something You Don’t!

The top talent that helped build some of the most successful biotech organizations in the industry, quickly taking therapies to market, and who had a hand in major acquisitions are now part of the leadership team with roles like Chief Executive Officer and Chief Medical Officer at a company that already has a pipeline of novel drug therapies.

SEE MORE DETAILS HERE!


Akcea Therapeutics Inc. (NASDAQ:AKCA) Announces Positive Phase 1/2 Results Of AKCEA-APOCIII-LRx

Akcea Therapeutics Inc. (NASDAQ:AKCA) has completed its Phase 1/2 clinical study of AKCEA-APOCIII-LRx have turned to be positive. The results presented at the American College of Cardiology (ACC) Annual Scientific Session have continued encouraging compliments given that it will be a solution designed to reduce the production of apolipoprotein C-III, or apoC-III.

SEE FOR YOURSELF CLICK HERE!


LEAVE A REPLY

Please enter your name here
Please enter your comment!